Free Trial

Wellington Management Group LLP Buys 1,883,481 Shares of Natera, Inc. (NASDAQ:NTRA)

Natera logo with Medical background

Wellington Management Group LLP lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 205.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,800,263 shares of the medical research company's stock after buying an additional 1,883,481 shares during the period. Wellington Management Group LLP owned approximately 2.12% of Natera worth $355,493,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in NTRA. SG Americas Securities LLC increased its stake in Natera by 1,073.1% during the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company's stock valued at $7,118,000 after buying an additional 60,127 shares during the period. Chartwell Investment Partners LLC increased its stake in shares of Natera by 37.9% during the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company's stock valued at $5,243,000 after acquiring an additional 11,362 shares during the period. Baader Bank Aktiengesellschaft bought a new stake in Natera during the second quarter worth approximately $478,000. Cerity Partners LLC lifted its position in Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company's stock worth $10,936,000 after purchasing an additional 18,316 shares during the period. Finally, Envestnet Portfolio Solutions Inc. boosted its stake in Natera by 50.6% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 13,622 shares of the medical research company's stock valued at $1,475,000 after purchasing an additional 4,575 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Natera news, CEO Steven Leonard Chapman sold 5,024 shares of the company's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now directly owns 195,686 shares in the company, valued at $25,141,737.28. This represents a 2.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Roelof Botha sold 87,473 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $169.12, for a total value of $14,793,433.76. Following the completion of the sale, the director now directly owns 1,224,787 shares in the company, valued at approximately $207,135,977.44. This represents a 6.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 133,976 shares of company stock worth $21,119,238. 7.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Robert W. Baird boosted their price objective on Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. The Goldman Sachs Group boosted their price target on shares of Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, October 16th. Canaccord Genuity Group raised their price objective on shares of Natera from $150.00 to $165.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. StockNews.com cut shares of Natera from a "hold" rating to a "sell" rating in a research note on Thursday, November 14th. Finally, JPMorgan Chase & Co. increased their target price on shares of Natera from $135.00 to $160.00 and gave the company an "overweight" rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $140.59.

Read Our Latest Stock Report on Natera

Natera Stock Up 1.6 %

NASDAQ NTRA traded up $2.63 during trading on Friday, reaching $171.65. The company's stock had a trading volume of 814,477 shares, compared to its average volume of 1,620,024. The stock has a market capitalization of $22.66 billion, a PE ratio of -97.53 and a beta of 1.63. The business has a 50-day moving average price of $140.16 and a 200-day moving average price of $122.53. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1-year low of $55.56 and a 1-year high of $175.63.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million during the quarter, compared to analysts' expectations of $361.43 million. During the same period in the prior year, the company posted ($0.95) earnings per share. Natera's revenue for the quarter was up 63.9% on a year-over-year basis. On average, research analysts forecast that Natera, Inc. will post -1.61 earnings per share for the current fiscal year.

About Natera

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Articles

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Should you invest $1,000 in Natera right now?

Before you consider Natera, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.

While Natera currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Future of Healthcare: 3 AI Stocks Leading the Way
Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines